J Allergy Clin Immunol
AAAAI 2026: Are asthma flares less common among adults with obesity taking GLP-1s?
Presented at the 2026 AAAAI Annual Meeting, a large real‑world cohort study using the TriNetX network found that initiating a GLP‑1 RA was associated with significantly fewer asthma exacerbations over three years in non‑diabetic adults with overweight, obesity, or morbid obesity. After propensity matching, GLP‑1 RA users had lower exacerbation rates across weight groups (risk ratios, 0.75–0.79), with risk differences of 12% to 15%—all statistically significant (p < 0.0001).
Clinical takeaway: When treating adults with asthma and obesity, consider whether GLP‑1 RAs (when otherwise appropriate) may provide added value by reducing exacerbation risk.
Source:
Patel R, et al. (2026, February). J Allergy Clin Immunol. Association between Glucagon-Like Peptide-1 Receptor Agonists and Asthma Exacerbations in Non-Diabetic Patients with Obesity: Cohort Study. https://www.jacionline.org/article/S0091-6749(25)01736-1/fulltext